Canadian brain imaging company Cubresa has signed a global master interface agreement with Siemens Healthineers for its BrainPET scanner.
The agreement will support the development and compatibility testing of Cubresa BrainPET scanners with Siemens Healthineers’ MAGNETOM MRI scanners, across all field strengths.
The contract will start with Siemens Healthineers MAGNETOM Terra and Terra.X 7T MRI scanners. Additional field strengths and models will be included later.
The Cubresa BrainPET is an investigational medical device that enhances magnetic resonance imaging (MRI) scanners with brain-optimised simultaneous positron emission tomography/magnetic resonance (PET/MR) imaging.
Its low-profile retrofit design makes it a cost-effective solution to add PET to existing MR suites without the need for new imaging suite facilities.
As a removable insert, BrainPET allows imaging centres to perform PET/MRI scans when needed and switch back to MRI-only scans as required.
The hybrid imaging capability streamlines the patient experience by conducting both scans in one session.
The PET insert is designed for 1.5T, 3T, and 7T MRI scanners that offer simultaneous PET/MR imaging capacity.
According to the brain imaging company, a custom MR transmit/receive coil ensures high-resolution MR images, and the system is compatible with MRI scanners from major vendors.
In June 2024, the Neuro at McGill University selected the BrainPET scanner to enhance their 7T MRI research programme, marking the first installation of BrainPET into a 7T MRI globally.
Cubresa founder and CEO James Schellenberg said: “Cubresa is proud to enter into this partnership with Siemens Healthineers.
“Our company has built a foundation on delivering innovative, high-quality PET scanners to our customers worldwide, and the relationship between Cubresa and Siemens Healthineers will build on this foundation. We look forward to many years of collaboration.”
The Cubresa BrainPET is a PET insert designed specifically for human brain imaging.
It retrofits into new and installed MRI scanners of all field strengths, making it ideal for clinical and research sites seeking the benefits of simultaneous PET/MR imaging.
The system is being developed for evaluating and monitoring neurological diseases, including brain cancers, epilepsy, and Alzheimer’s disease.
The BrainPET is an investigational device and is not yet available for commercial sale.
